These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19385721)

  • 21. [Raltegravir: the first HIV integrase inhibitor. Introduction].
    Gatell JM
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():1-2. PubMed ID: 19572418
    [No Abstract]   [Full Text] [Related]  

  • 22. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
    Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
    Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results.
    Elion R; Molina JM; Ramón Arribas López J; Cooper D; Maggiolo F; Wilkins E; Conway B; Liu YP; Margot N; Rhee M; Chuck SL; Szwarcberg J;
    J Acquir Immune Defic Syndr; 2013 Aug; 63(4):494-7. PubMed ID: 23807156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV integrase inhibitors: a new era in the treatment of HIV.
    Blanco JL; Whitlock G; Milinkovic A; Moyle G
    Expert Opin Pharmacother; 2015 Jun; 16(9):1313-24. PubMed ID: 26001181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use.
    Degli Antoni A; Weimer LE; Manfredi R; Fragola V; Ferrari C
    West Indian Med J; 2012 Dec; 61(9):932-6. PubMed ID: 24020238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Secondary effects associated with raltegravir].
    Gatell JM; Zamora L
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():34-9. PubMed ID: 19572424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of raltegravir in HIV/AIDS.
    Chaudhary MA; Elbasha EH; Kumar RN; Nathanson EC
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):627-39. PubMed ID: 22098278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.
    Evering TH; Markowitz M
    Drugs Today (Barc); 2007 Dec; 43(12):865-77. PubMed ID: 18174972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.
    Skiest DJ; Cohen C; Mounzer K; Haigney Z; Barker D; Gottlieb M; Bellman PC; Dejesus E; Khanlou H; Ruane PJ; Hsiao CB; Abriola K; Rashbaum B; Bellos N; Ward D; Colson A; Santiago F; Habel A; Garb J
    HIV Clin Trials; 2011; 12(3):131-40. PubMed ID: 21684853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Integrase inhibitor: raltegravir also as first line therapy].
    MMW Fortschr Med; 2010 Apr; 152(17):48. PubMed ID: 20509261
    [No Abstract]   [Full Text] [Related]  

  • 31. [Raltegravir - long lasting effectiveness, well tolerated and well combined].
    MMW Fortschr Med; 2013 Jun; 155 Suppl 1():30-1. PubMed ID: 23961651
    [No Abstract]   [Full Text] [Related]  

  • 32. Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir.
    Sedaghat AR; Siliciano RF; Wilke CO
    Antivir Ther; 2009; 14(2):263-71. PubMed ID: 19430101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.
    de Kanter CT; Blonk MI; Colbers AP; Schouwenberg BJ; Burger DM
    Clin Infect Dis; 2013 Jan; 56(2):300-6. PubMed ID: 23001704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics.
    Calcagno A; Montrucchio C; Capetti A; Guaraldi G; Cenderello G; Calza L; Lanzafame M; Marinaro L; Tettoni MC; Trentini L; D'Avolio A; Di Perri G; Bonora S
    Curr HIV Res; 2016; 14(1):54-60. PubMed ID: 26415700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrase inhibitors: a clinical review of raltegravir and elvitegravir.
    Grant P; Zolopa A
    J HIV Ther; 2008 Jun; 13(2):36-9. PubMed ID: 18953272
    [No Abstract]   [Full Text] [Related]  

  • 36. Report from the 2008 joint ICAAC/IDSA meeting. More on raltegravir: resistance and mechanisms of action.
    Albrecht H
    AIDS Clin Care; 2008 Dec; 20(12):97-8. PubMed ID: 19274773
    [No Abstract]   [Full Text] [Related]  

  • 37. Raltegravir use in special populations.
    Johnson M
    Eur J Med Res; 2009 Nov; 14 Suppl 3(Suppl 3):43-6. PubMed ID: 19959416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy.
    Ananworanich J; Gorowara M; Avihingsanon A; Kerr SJ; van Heesch N; Khongpetch C; Uanithirat A; Hill A; Ruxrungtham K; Burger DM;
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1892-8. PubMed ID: 22252825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-line raltegravir. No evidence of comparative effectiveness.
    Prescrire Int; 2010 Nov; 19(110):248-50. PubMed ID: 21284354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.